CMB International Securities | Equity Research | Sector Update



招商银行全资附属机 A A Wholly Owned Subsidiary Of China Merchants Ban

China Banking Sector

Assessing 2019-nCoV's impact

China banks' negative share price reaction due to concerns on nCoV appears overdone. We believe 2020E earnings downside is manageable at 4.8% max. Continued pro-growth policies and banks' solid provision buffer will likely mitigate the actual impact. The sector's defensive nature and near-trough valuation offer attractive risk-reward, in our view.

- Slower lending pace in 1Q20 but full-year outlook remains intact. Reduced economic activities during nCoV's outbreak will contain the demand of operation and consumption related loans by corporates and individuals. Assuming the epidemic is under control in Mar/Apr, we expect lending pace to accelerate in subsequent months driven by countercyclical measures, hence little impact to our full-year loan growth estimate (9.0% YoY for banks under coverage).
- A drag on fee income growth. Fee income from credit card, trade, and capital market related businesses might see slower growth in 1Q20. Those mostly generated through online channels, such as payment and wealth management fees, should see limited impact.
- Potential hit to asset quality. We believe a temporary rebound in overdue loans is unavoidable in 1Q20, mainly from corporates in wholesale & retail, transportation, and hotel & catering sectors (15.0% of total loans by 1H19). In particular, MSEs (5.1% of total loans by 1H19) in these industries are more vulnerable, as they are likely to suffer from cash flow problem on delayed operation and banks' falling risk appetite. However, to what extent overdue loans will transfer to NPLs largely depends on the effect of authorities' policy support.
- Liquidity loosening may add NIM pressure. CBIRC has called for greater credit support for borrowers affected by the epidemic, including loan extension/rollover and moderate cut in lending rate, etc. Meanwhile, PBoC conducted net liquidity injection of RMB 550bn in the past two days and cut reverse repo rate by 10bp on 3 Feb, suggesting increased likelihood of MLF and LPR rate cut ahead.
- Overall earnings impact capped at 4.8%. We attempt to quantify nCoV's possible impact to banks' 2020E earnings from four aspects: 1) 1.0ppt slowdown in loan growth, 2) 1.0ppt weakening in fee income growth, 3) 5bp increase in credit cost on rising defaults, and 4) 10bp decline in loan yield on regulators' window guidance, accompanied with interbank rate drop by the same magnitude. Based on our analysis, above four cases will trim the sector's 2020E net profit by 0.6%/0.4%/2.6%/1.2%, respectively. That said, actual impact would be smaller, as banks will likely use excess provision to cushion earnings volatility. We maintain our FY20E net profit growth forecast of 6.5% YoY for the sector.
- Valuation looks attractive. After 8.7%/9.2% YTD slump (vs 7.6%/5.4% for CSI300/HSI), A/H-share China banks trade at 0.74x/0.60x FY20E P/B, close to 1SD below historical mean. We believe recent market correction has created bottom-fishing opportunities. Top picks are PAB (000001 CH), CEB (6818 HK), and CCB (939 HK).

OUTPERFORM (Maintain)

China Banking Sector

Terry Sun, CFA (852) 3900 0836 terrysun@cmbi.com.hk



Source: Bloomberg, CMBIS

Valuation discount to historical mean

H-share	Price chg YTD	P/B (x)	Diff vs 5Y mean
ICBC	-11.8%	0.62	-11.6%
CCB	-9.7%	0.60	-13.0%
ABC	-12.0%	0.50	-19.3%
BOC	-8.1%	0.45	-21.0%
BoCom	-9.4%	0.45	-16.4%
CMB	-4.6%	1.33	17.7%
CITICB	-11.6%	0.38	-23.7%
MSB	-7.6%	0.44	-15.2%
CEB	-11.0%	0.44	-18.3%
PSBC	-6.4%	0.71	-6.3%
Average	-9.2%	0.60	-12.7%

Source: Bloomberg, CMBIS

Related Reports

- Proactive provisioning to beef up FY20E earnings – 23 Jan 2020
- 2. 3Q19 results wrap JSBs lead earnings recovery 31 Oct 2019
- Looking for a promising 4Q19 16
 Oct 2019
- Downside pressure in TSF persists –
 Sep 2019
- 2Q19 results wrap Lower credit cost offset falling margin – 2 Sep 2019





Figure 1: FY20E earnings sensitivity to potential impacts from nCoV outbreak

	Loan growth -1ppt	Fee growth -1ppt	Credit cost +5bp	Loan/interbank rate -10bp	Total
ICBC	-0.5%	-0.3%	-2.3%	-1.6%	-4.7%
CCB	-0.5%	-0.3%	-2.5%	-1.4%	-4.7%
ABC	-0.5%	-0.2%	-2.5%	-1.5%	-4.8%
BOC	-0.6%	-0.3%	-3.1%	-1.6%	-5.7%
BoCom	-0.9%	-0.4%	-2.9%	-1.0%	-5.1%
CITICB	-0.6%	-0.7%	-3.3%	-1.0%	-5.6%
MSB	-0.6%	-0.6%	-2.6%	-0.2%	-4.0%
CEB	-0.5%	-0.7%	-2.8%	-1.0%	-5.0%
PAB	-0.7%	-0.6%	-2.6%	-1.2%	-5.2%
Average	-0.6%	-0.4%	-2.6%	-1.2%	-4.8%

Source: Company data, CMBIS estimates

Figure 2: FY20E net profit impact from 1ppt decline Figure 3: FY20E net profit impact from 1ppt decline in in loan growth







Source: Company data, CMBIS estimates

Source: Company data, CMBIS estimates

Figure 4: FY20E net profit impact from 5bp rise in Figure 5: FY20E NIM and net profit impact from 10bp credit cost cut in loan and interbank rates





Source: Company data, CMBIS estimates

Source: Company data, CMBIS estimates



Figure 6: China banks loan breakdown by sector (1H19)

Loan sectors	ICBC	ССВ	ABC	ВОС	BoCom	PSBC	СМВ	CITICB	MSB	CEB	PAB
Corporate Ioans	62.9%	57.2%	60.6%	62.1%	67.7%	45.8%	48.2%	57.0%	59.4%	57.4%	41.2%
Manufacturing	10.2%	8.8%	10.4%	13.5%	12.0%	5.8%	6.1%	7.3%	8.8%	9.8%	5.2%
Transportation and postal services	13.3%	10.2%	12.2%	9.8%	11.5%	9.7%	7.0%	3.9%	2.0%	3.5%	1.7%
Wholesale and retail	3.7%	3.3%	3.1%	4.3%	4.7%	2.2%	3.9%	4.1%	5.3%	4.4%	5.5%
Electricity, gas and water supply	6.3%	5.8%	6.9%	5.3%	4.0%	4.0%	3.4%	2.0%	1.5%	1.7%	0.8%
Leasing and commercial services	7.6%	7.8%	8.0%	8.7%	-	2.0%	3.4%	7.7%	11.7%	6.3%	4.6%
Real estate	5.7%	4.4%	5.5%	8.0%	4.8%	1.4%	7.9%	7.9%	14.5%	8.1%	9.6%
Public utility	5.5%	3.0%	3.9%	2.5%	5.3%	1.5%	1.2%	6.2%	3.3%	9.3%	-
Construction	1.8%	2.5%	2.2%	2.1%	3.0%	2.1%	2.2%	2.5%	2.8%	3.3%	2.1%
Mining	1.4%	1.7%	1.7%	2.5%	2.3%	1.3%	0.9%	-	3.5%	-	1.6%
Others	7.4%	9.7%	6.9%	5.4%	20.0%	15.8%	12.1%	15.4%	5.9%	10.9%	10.1%
Retail loans	37.1%	42.8%	39.4%	37.9%	32.3%	54.2%	51.8%	43.0%	40.6%	42.6%	58.8%
Mortgage	30.2%	35.2%	30.3%	30.0%	20.9%	33.3%	24.0%	19.1%	11.0%	15.2%	9.0%
Credit card	3.9%	4.7%	3.5%	3.7%	8.9%	2.3%	15.1%	13.0%	13.1%	16.5%	24.5%
Others	3.0%	2.9%	5.6%	4.3%	2.6%	18.6%	12.7%	10.8%	16.4%	10.8%	25.3%

Source: Company data, CMBIS

Figure 7: MSE loan as % of total loans (1H19)





Figure 8: Interbank as % of total liabilities (3Q19)



Source: Company data, CMBIS

Source: Company data, CMBIS



Figure 9: Valuation summary

Company Ticker	Tieles	Last Price (HK\$)	TP (HK\$)	- Rating	P/B (x)		P/E (x)		Yield		ROE	
Company	mpany licker –				2019E	2020E	2019E	2020E	2019E	2020E	2019E	2020E
H-share												
ICBC	1398 HK	5.29	7.50	BUY	0.68	0.62	5.5	5.2	5.6%	5.9%	13.1%	12.6%
ССВ	939 HK	6.08	9.10	BUY	0.65	0.60	5.2	4.9	5.9%	6.2%	13.3%	12.8%
ABC	1288 HK	3.02	4.70	BUY	0.55	0.50	4.5	4.3	6.8%	7.2%	12.6%	12.2%
BOC	3988 HK	3.06	4.60	BUY	0.49	0.45	4.5	4.2	7.0%	7.3%	11.5%	11.1%
CITICB	998 HK	4.13	5.90	BUY	0.41	0.38	3.8	3.4	7.1%	7.8%	11.4%	11.5%
CEB	6818 HK	3.22	4.90	BUY	0.48	0.44	4.2	3.8	6.2%	6.9%	12.0%	12.1%
BoCom	3328 HK	5.02	6.20	HOLD	0.48	0.45	4.5	4.2	6.9%	7.3%	11.3%	11.0%
MSB	1988 HK	5.44	6.30	HOLD	0.48	0.44	4.0	3.8	7.5%	8.0%	12.3%	12.0%
PSBC	1658 HK	4.96	-	NR	0.78	0.71	6.5	5.8	4.6%	5.1%	12.4%	12.5%
CMB	3968 HK	38.20	-	NR	1.55	1.38	10.0	8.8	3.0%	3.4%	17.0%	16.6%
Average					0.66	0.60	5.3	4.8	6.1%	6.5%	13.1%	12.7%
A-share												
ICBC	601398 CH	5.50	7.80	BUY	0.79	0.72	6.3	6.0	4.8%	5.1%	13.1%	12.6%
CCB	601939 CH	6.68	9.40	BUY	0.80	0.73	6.3	6.0	4.8%	5.1%	13.3%	12.8%
ABC	601288 CH	3.42	5.10	BUY	0.69	0.63	5.7	5.4	5.4%	5.7%	12.6%	12.2%
BOC	601988 CH	3.50	5.00	BUY	0.63	0.58	5.7	5.4	5.5%	5.8%	11.5%	11.1%
CITICB	601998 CH	5.51	7.30	BUY	0.62	0.56	5.6	5.1	4.8%	5.2%	11.4%	11.5%
CEB	601818 CH	3.80	5.60	BUY	0.63	0.57	5.5	5.0	4.7%	5.2%	12.0%	12.1%
PAB	000001 CH	14.60	21.30	BUY	1.04	0.92	9.8	8.1	1.0%	1.3%	11.7%	12.1%
BoCom	601328 CH	5.20	6.50	HOLD	0.56	0.52	5.2	4.9	6.0%	6.3%	11.3%	11.0%
MSB	600016 CH	5.83	7.00	HOLD	0.57	0.52	4.8	4.5	6.3%	6.7%	12.3%	12.0%
PSBC	601658 CH	5.54	-	NR	0.99	0.90	8.1	7.1	3.7%	4.2%	12.4%	12.5%
CMB	600036 CH	35.35	-	NR	1.64	1.45	10.5	9.2	2.9%	3.3%	17.0%	16.6%
Average					0.81	0.74	6.7	6.1	4.5%	4.9%	13.0%	12.7%

Source: Bloomberg, CMBIS estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Disclosure

CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

CMBIS Ratings

BUY
Stock with potential return of over 15% over next 12 months
Control Stock with potential return of +15% to -10% over next 12 months
Control Stock with potential loss of over 10% over next 12 months
Control Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

This report is intended for distribution in the United States to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, and may not be furnished to any other person in the United States. Each major US, institutional investor that receives a copy of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.